Baird Maintains Acorda Therapeutics (ACOR) Neutral Rating, Says Takeout Still Seems Best Option
Tweet Send to a Friend
Baird reiterated its Neutral-rating and $32 price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) following mixed Ampyra revenue. The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
